Abstracts tagged "B-Lymphocyte"

Abstract Number: 0589 • ACR Convergence 2023
A Comparative Evaluation of IgA2 Anti-dsDNA Antibodies and Clinical Outcome in Two Clinical Trials of Belimumab After Rituximab in SLE
Muhammad RA Shipa¹, Daniel McCluskey¹, Laura Cooney² and Michael Ehrenstein¹, ¹University College London, London, United Kingdom, ²Immune Tolerance Network, Seattle, WA
Background/Purpose: We have shown that serum IgA2 anti-dsDNA antibody levels is a biomarker of response to belimumab after rituximab in SLE (BEAT-lupus trial) (1). We…
Abstract Number: 2124 • ACR Convergence 2023
Expansion of Atypical B Cells Accompanies Rheumatoid Arthritis-like Immune Dysregulation in ACPA+ At-risk Individuals
Adam Savage¹, Ziyuan He¹, Marla Glass¹, Julian Reading¹, LauraKay Moss², Marie Feser², Vlad Tsaltskan³, Katherine Nguyen Nguyen³, Kristen Demoruelle², kristine Kuhn⁴, David Boyle³, Cate Speake⁵, Xiao-Jun Li¹, Peter Skene¹, Troy Torgerson¹, Tom Bumol¹, V. Michael Holers⁶, Jane Buckner⁷, Gary Firestein⁸, kevin Deane² and Mark Gillespie¹, ¹Allen Institute for Immunology, Seattle, WA, ²University of Colorado Anschutz Medical Campus, Aurora, CO, ³University of California San Diego, La Jolla, CA, ⁴University of Colorado School of Medicine, Aurora, CO, ⁵Benaroya Research Institute, Seattle, WA, ⁶University of Colorado, Denver, CO, ⁷Benaroya Research Institute at Virginia Mason, Seattle, WA, ⁸University of California San Diego, San Diego, CA
Background/Purpose: Seropositive RA is preceded by an at-risk stage characterized by elevated circulating autoantibodies (AAb), including ACPA, in otherwise healthy individuals without clinically-apparent inflammatory arthritis.…
Abstract Number: 0607 • ACR Convergence 2023
CAR T Cell Therapy Leads to Long-term Abrogation of Autoimmunity in SLE Patients While Vaccination Responses Are Maintained
Georg Schett¹, Luis Munoz², Jule Taubmann³, Michael Aigner⁴, Christina Bergmann⁵, Johannes Knitza⁶, Gerhard Kroenke⁷, Dagmar Werner², Fabian Müller⁸ and Andreas Mackensen⁴, ¹Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ²FAU Erlangen-Nürnberg, Erlangen, Germany, ³Department of Internal Medicine 3, Rheumatology and Immunology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁴Department of Internal Medicine 5, Hematology and Oncology, Universitätsklinikum Erlangen and Friedrich-Alexander-Universität Erlangen Nürnberg, Erlangen, Germany, ⁵Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁶Department of Internal Medicine 3 Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, ⁷Charite Berlin, Berlin, Germany, ⁸Friedrich Alexander Universität Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany
Background/Purpose: We have previously shown that CD19 CAR T cell therapy leads to stable drug-free remission of treatment-resistant SLE (1,2). Based on these findings we…
Abstract Number: 2189 • ACR Convergence 2023
Lymphopenia Fluctuation Patterns Determine the Trajectory of the Disease in Sjogren’s Patients with Hematological Involvement
Giovanni Fulvio¹, Matilde Bandeira², Augusto Silva³, Gaetano La Rocca⁴, Silvia Fonzetti⁵, Francesco Ferro⁶, Marta Mosca⁷, Vasco Romão², Chiara Baldini¹, Manuel Silvério-António⁸ and Nikita Khmelinskii², ¹University of Pisa, Pisa, Italy, ²Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ³Santa Maria Hospital, Maceira, Portugal, ⁴University of Pisa, Rheumatology Unit, Pisa, Italy, ⁵AOUP, Pisa, Italy, ⁶Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy, ⁷Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ⁸Hospital Santa Maria, Lisboa, Portugal
Background/Purpose: Sjogren's disease (SjD) is characterized by a moderate prevalence of cytopenia, mainly neutropenia and lymphocytopenia with a typical fluctuating pattern. The associations between clinical…
Abstract Number: 0728 • ACR Convergence 2023
Systemic Lupus Erythematosus B Lymphocyte Responsiveness to Type I and Type III Interferon Is Determined by Donor IFN Status and B Cell Phenotype
Diana Alzamareh, Mary O'Connell, Jennifer Anolik and Jennifer Barnas, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematous (SLE) is a heterogenous autoimmune disorder characterized by pathogenic antinuclear antibodies. An interferon (IFN) gene signature and B cell aberrations are…
Abstract Number: 2341 • ACR Convergence 2023
Spanish National Registry of Belimumab in Patients with Systemic Lupus Erythematosus
María laiño¹, Monica Enguita², Javier Loricera³, Clara Moriano Morales⁴, Carmen Lasa⁵, Vanesa Calvo Río⁶, Javier Narvaez⁷, Pablo Ignacio Navarro Guerra⁸, Ivette Casafont-Sole⁹, Judit Font Urgelles¹⁰, Adela Gallego¹¹, Irene Carrión-Barberà¹², Patricia Quiroga¹³, Santos Castañeda¹³, Angel Garcia-Aparicio¹⁴, Joaquin Maria Belzunegui Otano¹⁵, Juan Ramon De Dios¹⁶, Marta López¹⁷, Samuel Hernandez¹⁸, Sergi Heredia Martin¹⁹, Aaron Fariñas²⁰, Francisco Navarro²¹, Jorge Juan Fragio²², Carmen Escudero²³, Rafaela Ortega Castro²⁴, Leticia del Olmo Perez²⁵, Valvanera Pinillos²⁶, Eztizen Labrador²⁶, Mamen Ortega²⁷, Patricia Castro Pérez²⁷, Juan Maria Blanco-Madrigal²⁸, Marcos Paulino²⁹, María Ángeles Matías³⁰, Enrique Calvo-Aranda³¹, Cilia Peralta³², Silvia García³³, Jordi Camins-Fàbregas³⁴, Marta Garijo Bufort³⁵, Dolores Fabregas³⁶, Ana Urruticoechea³⁷, Miguel Medina Malone³⁸, Piter Jose Cossio Jimenez³⁹, Eva Perez-Pampin⁴⁰, Blanca Varas de Dios⁴¹, Carlos Vazquez Galeano⁴², Nuria Vegas Revenga⁴³, Olga Rusinovich⁴⁴, Emilio Giner-Serret⁴⁵, Jose Ramón lamúa⁴⁶ and Vicente Aldasoro¹, ¹Hospital Universitario de Navarra, Pamplona, Spain, ²Navarrabiomed-Unidad de Metodología, Pamplona, Spain, ³Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario de León, León, Spain, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL., La Cavada, Spain, ⁶Valdecilla Hospital, Santander, Spain, ⁷Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario German Trias i Pujol,, Badalona, Spain, ¹¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴Hospital Universitario de Toledo, Toledo, Spain, ¹⁵University Hospital Donostia, Donostia-San Sebasti, Spain, ¹⁶Hospital Universitario Araba, Vitoria, Spain, ¹⁷Hospital Universitario Arava, Pamplona, Spain, ¹⁸Hospital Universitario Son Llatzer, Palma de Mallorca, Spain, ¹⁹Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁰Complejo Asistencial Universitario de Palencia, Palencia, Spain, ²¹Doctor. Rheumatology, Alicante, Spain, ²²Hospital General Universitario Valencia, Valencia, Spain, ²³Hospital Universitario de Valme, Sevilla, Spain, ²⁴Hospital Reina Sofía, Cordoba, Spain, ²⁵Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain, ²⁶Hospital Universitario San Pedro, Logroño, Spain, ²⁷Hospital Universitario de Getafe, Getafe, Spain, ²⁸Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ²⁹Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ³⁰Hospital Universitario Infanta Leonor/Rheumatology Department, Madrid, Spain, ³¹Hospital Universitario Infanta Leonor, Madrid, Spain, ³²Hospital Clínico Lozano Blesa, Zaragoza, Spain, ³³Hospital Parc Taulí, Sabadell, Spain, ³⁴Hospital General de Granollers, Granollers, Spain, ³⁵Hospital de Sagunto, Valencia, Spain, ³⁶Hospital de Barbastro, Barbastro, Spain, ³⁷Hospital Can Misses, Ibiza, Spain, ³⁸Hospital Calahorra, Calahorra, Spain, ³⁹HOSPITAL REINA SOFIA, Tudela, Spain, ⁴⁰Rheumatology Department Complejo Hospitalario Universitario Santiago, Santiago de compostela, Spain, ⁴¹Santa Cristina Universitary Hospital, Madrid, Spain, ⁴²ZARAGOZA, Madrid, Spain, ⁴³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴⁴Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ⁴⁵Hospital Royo Villanova, Teruel, Spain, ⁴⁶Hospital Universitario del Henares, Alcalá de Henares, Spain
Background/Purpose: Belimumab (BLM) is a monoclonal antibody that inhibits B-lymphocyte stimulating factor (BlyS), approved in 2011 as a treatment for systemic lupus erythematosus (SLE). We…
Abstract Number: 0152 • ACR Convergence 2022
Pm/Scl Patients Have an Expanded Population of CD19+CD21lo/negCD11c+CD11b+ Cells Expressing a Monocyte, Not B Cell, Transcriptome
Erin Wilfong, Leslie Crofford and Rachel Bonami, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: CD19 is considered a canonical B cell lineage marker. Previously, we have reported that CD19+CD21lo/negCD11c+ cells were increased in both systemic sclerosis [PMC8828801] as…
Abstract Number: 0784 • ACR Convergence 2022
Breakthrough SARS-CoV-2 Infections in Immune Mediated Disease Patients Undergoing B Cell Depleting Therapy: A Retrospective Cohort Analysis
Cassandra Calabrese¹, Elizabeth Kirchner², M. Elaine Husni³, Brandon Moss², Anthony Fernandez², Yuxuan Jin³ and Leonard Calabrese³, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Immunocompromised patients with immune mediated inflammatory diseases (IMIDs) undergoing therapy with B cell depleting agents (BCDT) are among the most vulnerable to severe COVID-19…
Abstract Number: 2065 • ACR Convergence 2022
Sustained B Cell Depletion in Lupus Nephritis Patients After Treatment with a B Cell Agent Is Associated with Fewer Disease Flares
Diane Zisa¹, Jeffrey Zhang-Sun¹, Paul Christos² and Kyriakos Kirou¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine/New York-Presbyterian, New York, NY
Background/Purpose: B cell targeting agents (BCA), including belimumab (BEL) and rituximab (RTX), have been used with success in lupus nephritis (LN) patients, though identifying patients…
Abstract Number: 0159 • ACR Convergence 2022
B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab
Tam Quach¹, Anne Davidson² and Galina Marder³, ¹Feinstein Institute for Medical Research, Manhasset, NY, ²Feinstein Institutes for Medical Research, Manhasset, NY, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Recent observations suggest the importance of the BAFF pathway in the pathogenesis of Idiopathic Inflammatory Myositis (IIM). Elevated serum levels of circulating BAFF in…
Abstract Number: 0979 • ACR Convergence 2022
Belimumab Effects on Skin in Patients with Systemic Lupus Erythematosus: A Pooled Post Hoc Analysis of Five Phase 3, Randomized, Placebo-Controlled Clinical Trials
Susan Manzi¹, Jorge Sanchez-Guerrero², Naoto Yokogawa³, Joerg Wenzel⁴, Josephine C. Ocran-Appiah⁵, Munther Khamashta⁶, Julia H N Harris⁷, Bernie Rubin⁸, Norma Lynn Fox⁹, Roger A Levy¹⁰ and Victoria Werth¹¹, ¹Allegheny Health Network, Lupus Center of Excellence, Wexford, PA, ²University of Toronto, Division of Rheumatology, Department of Medicine Mount Sinai Hospital/University Health Network, Toronto, ON, Canada, ³Tokyo Metropolitan Tama Medical Center, Department of Rheumatic Diseases, Tokyo, Japan, ⁴University Hospital of Bonn, Department of Dermatology and Allergy, Bonn, Germany, ⁵GlaxoSmithKline, Clinical Science Immunology, Rockville, MD, ⁶GlaxoSmithKline, Medical Affairs, Dubai, United Arab Emirates, ⁷GlaxoSmithKline, Immunology Biostatistics, Brentford, United Kingdom, ⁸GlaxoSmithKline, US Medical Affairs and Immuno-inflammation, Durham, NC, ⁹GlaxoSmithKline, Clinical Development *At time of study, Collegeville, PA, ¹⁰GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, ¹¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Mucocutaneous manifestations affect >80% of patients (pts) with SLE and can contribute to their poor quality of life through unwanted attention, self-consciousness, emotional symptoms,…
Abstract Number: 2183 • ACR Convergence 2022
mTORC2 Contributes to Murine Systemic Autoimmunity
Xian Zhou¹, Haiyu Qi¹, Meilu Li¹, Yanfeng Li¹, Xingxing Zhu², Anne Davidson³ and Hu Zeng¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Feinstein Institutes for Medical Research, Manhasset, NY
Background/Purpose: The development of many systemic autoimmune diseases, including systemic lupus erythematosus, is associated with overactivation of the type I interferon (IFN) pathway, lymphopenia, and…
Abstract Number: 0506 • ACR Convergence 2022
Immunophenotypic Categorization of Systemic Immune-mediated Diseases
Shinji Izuka¹, Toshihiko Komai¹, Takahiro Itamiya¹, Mineto Ota², Saeko Yamada¹, Yasuo Nagafuchi², Hirofumi Shoda¹, Kosuke Matsuki³, Kazuhiko Yamamoto⁴, Tomohisa Okamura² and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan, ³Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan, ⁴Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, the Institute of Physical and Chemical Research (RIKEN), Wako, Saitama, Japan
Background/Purpose: Systemic immune-mediated diseases are heterogeneous, and the pathogenesis varies among and within each disease. Some studies tried to stratify patients with immune-mediated diseases into…
Abstract Number: 0987 • ACR Convergence 2022
A Randomized Placebo-Controlled Phase 1 Study in Healthy Adult Volunteers of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALPN-303, a Potent Dual BAFF/APRIL Antagonist for the Treatment of Systemic Lupus Erythematosus and Other Autoantibody-Associated Diseases
Stacey Dillon¹, Pille Harrison², Jason Lickliter³, Kristi Manjarrez¹, Alina Smith¹, Mary Lessig¹, Lori Blanchfield¹, Russell Sanderson¹, Allison Chunyk¹, Tiffany Blair¹, Amanda Enstrom¹, Martin Wolfson¹, Mark Rixon¹, Hany Zayed⁴, Rupert Davies¹ and Stanford Peng¹, ¹Alpine Immune Sciences, Seattle, WA, ²Alpine Immune Sciences, Taunton, United Kingdom, ³Nucleus Network, Melbourne, Australia, ⁴Alpine Immune Sciences, San Francisco, CA
Background/Purpose: B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) are tumor necrosis factor (TNF) superfamily members that bind TACI (transmembrane activator and CAML…
Abstract Number: 0600 • ACR Convergence 2022
Correlates Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Phenotypes: Data from the Accelerated Medicines Partnership
Dana Weisenfeld¹, Fan Zhang², Laura Donlin³, Anna Jonsson¹, William Apruzzese¹, Debbie Campbell⁴, Ellen Gravallese⁵, Larry Moreland⁶, Susan Goodman³, Michael Brenner⁵, Soumya Raychaudhuri¹, Andrew Filer⁷, Jennifer Anolik⁸, Vivian Bykerk³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²University of Colorado, Aurora, CO, ³Hospital for Special Surgery, New York, NY, ⁴University of Rochester, Rochester, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶University of Colorado, Denver, CO, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University of Rochester Medical Center, Rochester, NY
Background/Purpose: Prior studies have characterized the diverse cell types in the RA synovium through a multi-center consortium incorporating RNA-seq data. Due to the novelty of…

« Previous Page
1
…
4
5
6
7
8
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].